Home / Indicator library / Biotechnology and Medical Care / Genmont (3164) overview
Genmont (3164) stock overview
Valuation, financials, growth, ownership, events, dividends, models and adjusted prices for Genmont, on one pageGenmont (3164) snapshot, key figures
Genmont (3164): where today sits in the past year
Current value against the 2025-07-31 to 2026-07-31 range, built from 243 frozen daily vintages.
Seven-dimension checkup for this ticker →
Valuation river
→Financial quality
→Revenue growth
→Ownership structure
→Events, last 90 days
→Yield river
→Valuation models
→Adjusted-price candles
→3164: common questions
What is 3164's P/E ratio?
3164 traded at a price-to-earnings ratio of 31.25x in the official-source snapshot dated 2026-08-03. That figure is frozen as a point-in-time vintage, so a backtest reading it sees only what was knowable that day.
What is 3164's price-to-book ratio?
3164's price-to-book ratio was 1.09x on 2026-08-03, taken as-is from the official public source.
What is 3164's dividend yield?
3164's cash dividend yield was 4.92% on 2026-08-03. Historical dividend policy and gap-fill records are available on the same page.
How fast is 3164's revenue growing?
3164 reported -13.2% year-on-year monthly revenue growth for 2026-06, from the official monthly revenue filing.
Is 3164's price / earnings high or low right now?
3164's price / earnings is 31.25x, which is below its one-year median of 45.00x and sits at the 21st percentile of the 26.52–112.78x range observed over the last 243 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.
Is 3164's price / book high or low right now?
3164's price / book is 1.09x, which is below its one-year median of 1.21x and sits at the 9th percentile of the 1.06–1.42x range observed over the last 243 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.
Other Biotechnology and Medical Care tickers
160 Taiwan-listed tickers sit in this sector. See the full Biotechnology and Medical Care table.